Global Cord Blood (NYSE:CO) Earns Strong-Buy Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Global Cord Blood (NYSE:COFree Report) in a report issued on Wednesday morning. The firm issued a strong-buy rating on the medical research company’s stock.

Global Cord Blood Price Performance

Shares of CO stock opened at $1.15 on Wednesday. The stock has a market cap of $139.78 million, a P/E ratio of 1.80 and a beta of 0.16. The company has a fifty day moving average price of $1.04 and a two-hundred day moving average price of $1.32. Global Cord Blood has a one year low of $2.03 and a one year high of $5.50.

Global Cord Blood Company Profile

(Get Free Report)

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.

Further Reading

Receive News & Ratings for Global Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Cord Blood and related companies with MarketBeat.com's FREE daily email newsletter.